{"id":31417,"date":"2022-11-01T15:20:48","date_gmt":"2022-11-01T10:20:48","guid":{"rendered":"https:\/\/pr.asianetpakistan.com\/?p=101295"},"modified":"2022-11-01T15:20:48","modified_gmt":"2022-11-01T10:20:48","slug":"jeito-capital-becomes-a-significant-investor-in-hi-bio-a-clinical-stage-biotech-company-developing-targeted-therapies-for-patients-with-severe-immune-mediated-diseases-2","status":"publish","type":"post","link":"https:\/\/myanmarnewsgazette.com\/jeito-capital-becomes-a-significant-investor-in-hi-bio-a-clinical-stage-biotech-company-developing-targeted-therapies-for-patients-with-severe-immune-mediated-diseases-2\/","title":{"rendered":"Jeito Capital becomes a significant investor in HI-Bio, a clinical-stage biotech company developing targeted therapies for patients with severe immune-mediated diseases"},"content":{"rendered":"<p><strong>Jeito Capital\u00a0<\/strong><strong>becomes a significant\u00a0<\/strong><strong>invest<\/strong><strong>or<\/strong><strong>\u00a0in\u00a0<\/strong><strong>HI-Bio<\/strong><strong>,<\/strong><strong>\u00a0a<\/strong><strong>\u00a0clinical-stage biotech company developing targeted therapies for patients with severe immune-mediated diseases<\/strong><\/p>\n<ul type=\"disc\">\n<li>Jeito Capital participates in $120 million financing alongside ARCH Venture Partners and Monograph Capital\n<ul type=\"disc\">\n<li>HI-Bio is a San Francisco-based clinical-stage biotechnology company developing targeted therapies for patients with severe immune-mediated diseases<\/li>\n<li>Investment marks Jeito\u2019s first investment in the United States demonstrating its ambition to build a solid and diversified portfolio of international investments in healthcare companies across therapeutic areas of high unmet need<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p align=\"justify\"><strong>Paris, France,\u00a0<\/strong><strong>November\u00a0<\/strong><strong>1<\/strong><sup><strong>st<\/strong><\/sup>\u00a0<strong>2022<\/strong>\u00a0&#8211; Jeito Capital (&#8220;Jeito&#8221;), a leading independent international private equity firm dedicated to biopharma, announced today that it has participated in the $120 million financing of Human Immunology Biosciences (HI-Bio<img decoding=\"async\" src=\"https:\/\/s.w.org\/images\/core\/emoji\/14.0.0\/72x72\/2122.png\" alt=\"\u2122\" class=\"wp-smiley\" style=\"height: 1em; max-height: 1em;\" \/>), a clinical-stage biotech company developing targeted therapies for patients suffering from severe immune-mediated diseases (IMD). Jeito Capital joins a syndicate of world class investors including ARCH Venture Partners and Monograph Capital in backing the San Francisco-based company.<\/p>\n<p align=\"justify\">The investment in HI-Bio is Jeito\u2019s 11<sup>th<\/sup>\u00a0to date and its first in the United States, demonstrating the fund\u2019s ambition to build a global and diverse portfolio of companies operating in numerous therapeutic areas of unmet need for patients and at different stages of development (from pre-clinical to advanced clinical-stage).<\/p>\n<p align=\"justify\">HI-Bio has multiple clinical-stage programs and a strong translational platform with the potential to address several diseases with unmet medical needs. Few targeted therapies exist for patients affected by IMDs, which include autoimmune, allergic and inflammatory diseases. Conventional therapies are generally broad-acting and do not address the root cause of disease. As a result, many patients with IMDs experience limited relief from symptoms and may experience unnecessary side effects.<\/p>\n<p align=\"justify\">Nearly 4% of the world&#8217;s population is potentially affected by one of these diseases, and more than half of those treated with currently available therapies are not in remission. With such large unmet medical patient need, the global therapeutic market for these diseases could reach $150 billion by 2025.<\/p>\n<p align=\"justify\">Many IMDs stem from the dysfunction of cells that make up the immune system, including plasma cells, neutrophils, mast cells and more. These cells are responsible for critical functions and processes, including the secretion of antibodies, signaling mediators, and tissue repair and allergic responses. HI-Bio\u2019s programs apply a precision medicine approach to target, modulate or deplete these cellular drivers of disease with therapeutics.<\/p>\n<p align=\"justify\"><strong>Dr Rafa\u00e8le\u00a0<\/strong><strong>Tordjman<\/strong><strong>, founder and CEO of Jeito, commented:<\/strong>\u00a0\u201cJeito\u2019s investment in HI-Bio, alongside distinguished investors such as ARCH Venture Partners and Monograph Capital, represents an important step as we make our first investment in the United States, further demonstrating our ambition to support international companies developing groundbreaking therapies in areas of high unmet need. HI-Bio is launching with a team of renowned experts with impressive track records and a pipeline of precision therapies that have the potential to address unmet patient needs around the world today.\u201d<\/p>\n<p align=\"justify\"><strong>Rachel Mears, Partner\u00a0<\/strong><strong>at<\/strong><strong>\u00a0Jeito, added<\/strong>: \u201cJeito\u2019s investment supports the important work by HI-Bio on behalf of patients suffering from immune-mediated diseases. The potential to reduce the enormous health burden for these patients using HI-Bio\u2019s precision medicine approach was a key motivator for this investment. With HI-Bio\u2019s ongoing clinical programs and its strong pipeline of additional development candidates, Jeito\u2019s strategy to invest behind strong teams founded on great science and positioned for growth driven by making a difference for patients fits hand-in-hand with HI-Bio.\u201d<\/p>\n<p align=\"justify\"><strong>Travis Murdoch, M.D., CEO of\u00a0<\/strong><strong>HI-Bio<\/strong><strong>\u00a0concluded<\/strong>: \u201cWe at HI-Bio are an embodiment of the urgent need to develop precision therapies that are more targeted for patients suffering from immune-mediated diseases. Immune-mediated diseases represent a landscape where the scale of unmet need and potential patient benefit is truly enormous. We are grateful to our investors Jeito Capital, ARCH and Monograph who share our vision for HI-Bio. They see that we have an actionable opportunity to bring an unprecedented degree of precision and creativity to clinical immunology, with all the potential safety and efficacy enhancements that come with our approach.\u201d<\/p>\n<p align=\"justify\"><strong>About Jeito Capital<\/strong><br \/>\nJeito Capital is a global leading investment company with a patient benefit driven approach that finances and accelerates the development and growth of ground-breaking medical innovation. Jeito empowers and supports entrepreneurs through its expert, integrated, multi-talented team and through the investment of significant capital to ensure the growth of companies, building market leaders in their respective therapeutic areas with accelerated patients\u2019 access globally, especially in Europe and the United States. Jeito Capital has \u20ac534 million under management and a rapidly growing portfolio of investments. Jeito Capital is based in Paris with a presence in Europe and the United States.<\/p>\n<p align=\"justify\"><a href=\"https:\/\/www.google.com\/url?q=https:\/\/www.globenewswire.com\/Tracker?data%3DEEP8YWl1yDNPin9h21wjQiV7MP9ob6vNIjzNousfvt7BBG1a4VtOHJPjTR1U_6hE0l_6_OlgY2DcdPIfVGfAeyuVT3o0TH_HvHles-RDSA4%3D&amp;source=gmail-html&amp;ust=1667402466123000&amp;usg=AOvVaw08aXAJMg8EaZ1jjUrtcf5h\"  rel=\"nofollow noopener noreferrer\"><u>@Jeito_life<\/u><\/a><a href=\"https:\/\/www.google.com\/url?q=https:\/\/www.globenewswire.com\/Tracker?data%3DptUan6FetsuqAog16Wd56qhRDFw-715JHUgArkFnJekD2cVoeoMG49LzVIUOH0Z3rE4uaUyY3Qdq467M6K_MLXpOZDmq-iuc77rD2FDMAt6ddUbA8VqptsyWRz1sLthXQ2DN5ukuzcM12O8zq9cdeg%3D%3D&amp;source=gmail-html&amp;ust=1667402466123000&amp;usg=AOvVaw0mFOG2_I_PYmrSktV5vp1e\"  rel=\"nofollow noopener noreferrer\"><u>LinkedIn<\/u><\/a>\u00a0For more information, please visit www.jeito.life, or follow\u00a0<a href=\"https:\/\/www.google.com\/url?q=https:\/\/www.globenewswire.com\/Tracker?data%3DEEP8YWl1yDNPin9h21wjQsaBy35XC7LMtGceaNAwIi0Y3OeE3Nyer4fOakB1z1SaLI2b1xMBUvFTGNiH21qR7HETsJrJYVuVGKaPtvL-Iyc%3D&amp;source=gmail-html&amp;ust=1667402466124000&amp;usg=AOvVaw1IyfygwccwabjRqbH2qlv1\"  rel=\"nofollow noopener noreferrer\"><u>@Jeito_life<\/u><\/a>\u00a0on Twitter or\u00a0<a href=\"https:\/\/www.google.com\/url?q=https:\/\/www.globenewswire.com\/Tracker?data%3DptUan6FetsuqAog16Wd56skGpUXSKJGgYoWqUiykT5qXRbJ8RZGI_BTeaC17495bV0BcyFouofxb-vh5PALFucULNGu4IOMzT4zzDYnMM9zpl-GFdn50jDRc7S_y7ndkCjqeWVKNWPwJPzcZF00_HA%3D%3D&amp;source=gmail-html&amp;ust=1667402466124000&amp;usg=AOvVaw2fAUcbrieEt9Qat0q4noqO\"  rel=\"nofollow noopener noreferrer\"><u>LinkedIn<\/u><\/a>.<\/p>\n<p align=\"justify\"><strong>For further information please contact\u00a0<\/strong>:<\/p>\n<p><strong>Jeito Capital<\/strong><br \/>\nRafa\u00e8le Tordjman<br \/>\nAssia Mouhout, PA<br \/>\n<a href=\"https:\/\/www.google.com\/url?q=https:\/\/www.globenewswire.com\/Tracker?data%3DyryoZU7TR7b8ebK3Thl73RnP0JGvvLcRz8hYVvCggsstbV_LK40cKSGfhsyNBGYnpCI_5fvXK6W3oyqz67EesA%3D%3D&amp;source=gmail-html&amp;ust=1667402466124000&amp;usg=AOvVaw1WQ6oP0K3McgVAJOn6HMFi\"  rel=\"nofollow noopener noreferrer\"><u>assia@jeito.life<\/u><\/a><br \/>\nTel : +33 6 76 49 37 94<\/p>\n<p align=\"justify\"><strong>Consilium Strategic Communications<\/strong><\/p>\n<p align=\"justify\">Mary-Jane Elliott \/ Davide Salvi \/ Kris Lam<\/p>\n<p align=\"justify\"><a href=\"mailto:Jeito@consilium-comms.com\"  rel=\"noopener noreferrer\">Jeito@consilium-comms.com<\/a><\/p>\n<p align=\"justify\">Tel: +44 (0) 20 3709 5700<\/p>\n<p id=\"m_gnw_attachments_section-header\"><strong>Attachment<\/strong><\/p>\n<ul id=\"m_gnw_attachments_section-items\">\n<li><a href=\"https:\/\/www.google.com\/url?q=https:\/\/ml-eu.globenewswire.com\/Resource\/Download\/ffac2025-085e-4d8f-b2e3-06bf165ba8b9&amp;source=gmail-html&amp;ust=1667402466124000&amp;usg=AOvVaw3L1bRRfsOD2CPlq4RUSGqk\"  rel=\"noopener noreferrer\">20221101_CP Jeito investit dans HI-Bio<\/a><\/li>\n<\/ul>\n<p style=\"text-align: center;\">GlobeNewswire Distribution ID 1000754169<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Jeito Capital\u00a0becomes a significant\u00a0investor\u00a0in\u00a0HI-Bio,\u00a0a\u00a0clinical-stage biotech company developing targeted therapies for patients with severe immune-mediated diseases Jeito Capital participates in $120 million financing alongside ARCH Venture Partners and Monograph Capital HI-Bio is a San Francisco-based clinical-stage biotechnology company developing targeted therapies for patients with severe immune-mediated diseases Investment marks Jeito\u2019s first investment in the United States [\u2026]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[14],"tags":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.3 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Jeito Capital becomes a significant investor in HI-Bio, a clinical-stage biotech company developing targeted therapies for patients with severe immune-mediated diseases - Myanmar News Gazette<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/myanmarnewsgazette.com\/jeito-capital-becomes-a-significant-investor-in-hi-bio-a-clinical-stage-biotech-company-developing-targeted-therapies-for-patients-with-severe-immune-mediated-diseases-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Jeito Capital becomes a significant investor in HI-Bio, a clinical-stage biotech company developing targeted therapies for patients with severe immune-mediated diseases - Myanmar News Gazette\" \/>\n<meta property=\"og:description\" content=\"Jeito Capital\u00a0becomes a significant\u00a0investor\u00a0in\u00a0HI-Bio,\u00a0a\u00a0clinical-stage biotech company developing targeted therapies for patients with severe immune-mediated diseases Jeito Capital participates in $120 million financing alongside ARCH Venture Partners and Monograph Capital HI-Bio is a San Francisco-based clinical-stage biotechnology company developing targeted therapies for patients with severe immune-mediated diseases Investment marks Jeito\u2019s first investment in the United States [\u2026]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/myanmarnewsgazette.com\/jeito-capital-becomes-a-significant-investor-in-hi-bio-a-clinical-stage-biotech-company-developing-targeted-therapies-for-patients-with-severe-immune-mediated-diseases-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Myanmar News Gazette\" \/>\n<meta property=\"article:published_time\" content=\"2022-11-01T10:20:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/s.w.org\/images\/core\/emoji\/14.0.0\/72x72\/2122.png\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/myanmarnewsgazette.com\/jeito-capital-becomes-a-significant-investor-in-hi-bio-a-clinical-stage-biotech-company-developing-targeted-therapies-for-patients-with-severe-immune-mediated-diseases-2\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/myanmarnewsgazette.com\/jeito-capital-becomes-a-significant-investor-in-hi-bio-a-clinical-stage-biotech-company-developing-targeted-therapies-for-patients-with-severe-immune-mediated-diseases-2\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/myanmarnewsgazette.com\/#\/schema\/person\/c7e2b10e6a2fda5bcbb164cc7b208a0f\"},\"headline\":\"Jeito Capital becomes a significant investor in HI-Bio, a clinical-stage biotech company developing targeted therapies for patients with severe immune-mediated diseases\",\"datePublished\":\"2022-11-01T10:20:48+00:00\",\"dateModified\":\"2022-11-01T10:20:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/myanmarnewsgazette.com\/jeito-capital-becomes-a-significant-investor-in-hi-bio-a-clinical-stage-biotech-company-developing-targeted-therapies-for-patients-with-severe-immune-mediated-diseases-2\/\"},\"wordCount\":843,\"publisher\":{\"@id\":\"https:\/\/myanmarnewsgazette.com\/#organization\"},\"image\":{\"@id\":\"https:\/\/myanmarnewsgazette.com\/jeito-capital-becomes-a-significant-investor-in-hi-bio-a-clinical-stage-biotech-company-developing-targeted-therapies-for-patients-with-severe-immune-mediated-diseases-2\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/s.w.org\/images\/core\/emoji\/14.0.0\/72x72\/2122.png\",\"articleSection\":[\"Press Releases\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/myanmarnewsgazette.com\/jeito-capital-becomes-a-significant-investor-in-hi-bio-a-clinical-stage-biotech-company-developing-targeted-therapies-for-patients-with-severe-immune-mediated-diseases-2\/\",\"url\":\"https:\/\/myanmarnewsgazette.com\/jeito-capital-becomes-a-significant-investor-in-hi-bio-a-clinical-stage-biotech-company-developing-targeted-therapies-for-patients-with-severe-immune-mediated-diseases-2\/\",\"name\":\"Jeito Capital becomes a significant investor in HI-Bio, a clinical-stage biotech company developing targeted therapies for patients with severe immune-mediated diseases - Myanmar News Gazette\",\"isPartOf\":{\"@id\":\"https:\/\/myanmarnewsgazette.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/myanmarnewsgazette.com\/jeito-capital-becomes-a-significant-investor-in-hi-bio-a-clinical-stage-biotech-company-developing-targeted-therapies-for-patients-with-severe-immune-mediated-diseases-2\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/myanmarnewsgazette.com\/jeito-capital-becomes-a-significant-investor-in-hi-bio-a-clinical-stage-biotech-company-developing-targeted-therapies-for-patients-with-severe-immune-mediated-diseases-2\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/s.w.org\/images\/core\/emoji\/14.0.0\/72x72\/2122.png\",\"datePublished\":\"2022-11-01T10:20:48+00:00\",\"dateModified\":\"2022-11-01T10:20:48+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/myanmarnewsgazette.com\/jeito-capital-becomes-a-significant-investor-in-hi-bio-a-clinical-stage-biotech-company-developing-targeted-therapies-for-patients-with-severe-immune-mediated-diseases-2\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/myanmarnewsgazette.com\/jeito-capital-becomes-a-significant-investor-in-hi-bio-a-clinical-stage-biotech-company-developing-targeted-therapies-for-patients-with-severe-immune-mediated-diseases-2\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/myanmarnewsgazette.com\/jeito-capital-becomes-a-significant-investor-in-hi-bio-a-clinical-stage-biotech-company-developing-targeted-therapies-for-patients-with-severe-immune-mediated-diseases-2\/#primaryimage\",\"url\":\"https:\/\/s.w.org\/images\/core\/emoji\/14.0.0\/72x72\/2122.png\",\"contentUrl\":\"https:\/\/s.w.org\/images\/core\/emoji\/14.0.0\/72x72\/2122.png\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/myanmarnewsgazette.com\/jeito-capital-becomes-a-significant-investor-in-hi-bio-a-clinical-stage-biotech-company-developing-targeted-therapies-for-patients-with-severe-immune-mediated-diseases-2\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/myanmarnewsgazette.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Jeito Capital becomes a significant investor in HI-Bio, a clinical-stage biotech company developing targeted therapies for patients with severe immune-mediated diseases\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/myanmarnewsgazette.com\/#website\",\"url\":\"https:\/\/myanmarnewsgazette.com\/\",\"name\":\"Myanmar News Gazette\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/myanmarnewsgazette.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/myanmarnewsgazette.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/myanmarnewsgazette.com\/#organization\",\"name\":\"Myanmar News Gazette\",\"url\":\"https:\/\/myanmarnewsgazette.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/myanmarnewsgazette.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/myanmarnewsgazette.com\/wp-content\/uploads\/2022\/07\/Myanmar-logo.png\",\"contentUrl\":\"https:\/\/myanmarnewsgazette.com\/wp-content\/uploads\/2022\/07\/Myanmar-logo.png\",\"width\":200,\"height\":200,\"caption\":\"Myanmar News Gazette\"},\"image\":{\"@id\":\"https:\/\/myanmarnewsgazette.com\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/myanmarnewsgazette.com\/#\/schema\/person\/c7e2b10e6a2fda5bcbb164cc7b208a0f\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/myanmarnewsgazette.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/ff4aa10d4f36ab9dc3cce9e101792273?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/ff4aa10d4f36ab9dc3cce9e101792273?s=96&d=mm&r=g\",\"caption\":\"admin\"},\"url\":\"https:\/\/myanmarnewsgazette.com\/author\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Jeito Capital becomes a significant investor in HI-Bio, a clinical-stage biotech company developing targeted therapies for patients with severe immune-mediated diseases - Myanmar News Gazette","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/myanmarnewsgazette.com\/jeito-capital-becomes-a-significant-investor-in-hi-bio-a-clinical-stage-biotech-company-developing-targeted-therapies-for-patients-with-severe-immune-mediated-diseases-2\/","og_locale":"en_US","og_type":"article","og_title":"Jeito Capital becomes a significant investor in HI-Bio, a clinical-stage biotech company developing targeted therapies for patients with severe immune-mediated diseases - Myanmar News Gazette","og_description":"Jeito Capital\u00a0becomes a significant\u00a0investor\u00a0in\u00a0HI-Bio,\u00a0a\u00a0clinical-stage biotech company developing targeted therapies for patients with severe immune-mediated diseases Jeito Capital participates in $120 million financing alongside ARCH Venture Partners and Monograph Capital HI-Bio is a San Francisco-based clinical-stage biotechnology company developing targeted therapies for patients with severe immune-mediated diseases Investment marks Jeito\u2019s first investment in the United States [\u2026]","og_url":"https:\/\/myanmarnewsgazette.com\/jeito-capital-becomes-a-significant-investor-in-hi-bio-a-clinical-stage-biotech-company-developing-targeted-therapies-for-patients-with-severe-immune-mediated-diseases-2\/","og_site_name":"Myanmar News Gazette","article_published_time":"2022-11-01T10:20:48+00:00","og_image":[{"url":"https:\/\/s.w.org\/images\/core\/emoji\/14.0.0\/72x72\/2122.png"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/myanmarnewsgazette.com\/jeito-capital-becomes-a-significant-investor-in-hi-bio-a-clinical-stage-biotech-company-developing-targeted-therapies-for-patients-with-severe-immune-mediated-diseases-2\/#article","isPartOf":{"@id":"https:\/\/myanmarnewsgazette.com\/jeito-capital-becomes-a-significant-investor-in-hi-bio-a-clinical-stage-biotech-company-developing-targeted-therapies-for-patients-with-severe-immune-mediated-diseases-2\/"},"author":{"name":"admin","@id":"https:\/\/myanmarnewsgazette.com\/#\/schema\/person\/c7e2b10e6a2fda5bcbb164cc7b208a0f"},"headline":"Jeito Capital becomes a significant investor in HI-Bio, a clinical-stage biotech company developing targeted therapies for patients with severe immune-mediated diseases","datePublished":"2022-11-01T10:20:48+00:00","dateModified":"2022-11-01T10:20:48+00:00","mainEntityOfPage":{"@id":"https:\/\/myanmarnewsgazette.com\/jeito-capital-becomes-a-significant-investor-in-hi-bio-a-clinical-stage-biotech-company-developing-targeted-therapies-for-patients-with-severe-immune-mediated-diseases-2\/"},"wordCount":843,"publisher":{"@id":"https:\/\/myanmarnewsgazette.com\/#organization"},"image":{"@id":"https:\/\/myanmarnewsgazette.com\/jeito-capital-becomes-a-significant-investor-in-hi-bio-a-clinical-stage-biotech-company-developing-targeted-therapies-for-patients-with-severe-immune-mediated-diseases-2\/#primaryimage"},"thumbnailUrl":"https:\/\/s.w.org\/images\/core\/emoji\/14.0.0\/72x72\/2122.png","articleSection":["Press Releases"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/myanmarnewsgazette.com\/jeito-capital-becomes-a-significant-investor-in-hi-bio-a-clinical-stage-biotech-company-developing-targeted-therapies-for-patients-with-severe-immune-mediated-diseases-2\/","url":"https:\/\/myanmarnewsgazette.com\/jeito-capital-becomes-a-significant-investor-in-hi-bio-a-clinical-stage-biotech-company-developing-targeted-therapies-for-patients-with-severe-immune-mediated-diseases-2\/","name":"Jeito Capital becomes a significant investor in HI-Bio, a clinical-stage biotech company developing targeted therapies for patients with severe immune-mediated diseases - Myanmar News Gazette","isPartOf":{"@id":"https:\/\/myanmarnewsgazette.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/myanmarnewsgazette.com\/jeito-capital-becomes-a-significant-investor-in-hi-bio-a-clinical-stage-biotech-company-developing-targeted-therapies-for-patients-with-severe-immune-mediated-diseases-2\/#primaryimage"},"image":{"@id":"https:\/\/myanmarnewsgazette.com\/jeito-capital-becomes-a-significant-investor-in-hi-bio-a-clinical-stage-biotech-company-developing-targeted-therapies-for-patients-with-severe-immune-mediated-diseases-2\/#primaryimage"},"thumbnailUrl":"https:\/\/s.w.org\/images\/core\/emoji\/14.0.0\/72x72\/2122.png","datePublished":"2022-11-01T10:20:48+00:00","dateModified":"2022-11-01T10:20:48+00:00","breadcrumb":{"@id":"https:\/\/myanmarnewsgazette.com\/jeito-capital-becomes-a-significant-investor-in-hi-bio-a-clinical-stage-biotech-company-developing-targeted-therapies-for-patients-with-severe-immune-mediated-diseases-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/myanmarnewsgazette.com\/jeito-capital-becomes-a-significant-investor-in-hi-bio-a-clinical-stage-biotech-company-developing-targeted-therapies-for-patients-with-severe-immune-mediated-diseases-2\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/myanmarnewsgazette.com\/jeito-capital-becomes-a-significant-investor-in-hi-bio-a-clinical-stage-biotech-company-developing-targeted-therapies-for-patients-with-severe-immune-mediated-diseases-2\/#primaryimage","url":"https:\/\/s.w.org\/images\/core\/emoji\/14.0.0\/72x72\/2122.png","contentUrl":"https:\/\/s.w.org\/images\/core\/emoji\/14.0.0\/72x72\/2122.png"},{"@type":"BreadcrumbList","@id":"https:\/\/myanmarnewsgazette.com\/jeito-capital-becomes-a-significant-investor-in-hi-bio-a-clinical-stage-biotech-company-developing-targeted-therapies-for-patients-with-severe-immune-mediated-diseases-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/myanmarnewsgazette.com\/"},{"@type":"ListItem","position":2,"name":"Jeito Capital becomes a significant investor in HI-Bio, a clinical-stage biotech company developing targeted therapies for patients with severe immune-mediated diseases"}]},{"@type":"WebSite","@id":"https:\/\/myanmarnewsgazette.com\/#website","url":"https:\/\/myanmarnewsgazette.com\/","name":"Myanmar News Gazette","description":"","publisher":{"@id":"https:\/\/myanmarnewsgazette.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/myanmarnewsgazette.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/myanmarnewsgazette.com\/#organization","name":"Myanmar News Gazette","url":"https:\/\/myanmarnewsgazette.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/myanmarnewsgazette.com\/#\/schema\/logo\/image\/","url":"https:\/\/myanmarnewsgazette.com\/wp-content\/uploads\/2022\/07\/Myanmar-logo.png","contentUrl":"https:\/\/myanmarnewsgazette.com\/wp-content\/uploads\/2022\/07\/Myanmar-logo.png","width":200,"height":200,"caption":"Myanmar News Gazette"},"image":{"@id":"https:\/\/myanmarnewsgazette.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/myanmarnewsgazette.com\/#\/schema\/person\/c7e2b10e6a2fda5bcbb164cc7b208a0f","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/myanmarnewsgazette.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/ff4aa10d4f36ab9dc3cce9e101792273?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/ff4aa10d4f36ab9dc3cce9e101792273?s=96&d=mm&r=g","caption":"admin"},"url":"https:\/\/myanmarnewsgazette.com\/author\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/myanmarnewsgazette.com\/wp-json\/wp\/v2\/posts\/31417"}],"collection":[{"href":"https:\/\/myanmarnewsgazette.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/myanmarnewsgazette.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/myanmarnewsgazette.com\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/myanmarnewsgazette.com\/wp-json\/wp\/v2\/comments?post=31417"}],"version-history":[{"count":0,"href":"https:\/\/myanmarnewsgazette.com\/wp-json\/wp\/v2\/posts\/31417\/revisions"}],"wp:attachment":[{"href":"https:\/\/myanmarnewsgazette.com\/wp-json\/wp\/v2\/media?parent=31417"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/myanmarnewsgazette.com\/wp-json\/wp\/v2\/categories?post=31417"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/myanmarnewsgazette.com\/wp-json\/wp\/v2\/tags?post=31417"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}